Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Amphotericin B for Resistant Tinea Capitis
NCT06980493Phase 3Active, not recruiting
- Sponsor
- Sohag University
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amphotericin B liposomal in tinea capitis, sponsored by Sohag University. Primary endpoint: Reduction in size of scaling at 8 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
amphotericin B liposomal
03
Conditions
tinea capitis
Beyond the preview
Go deeper on NCT06980493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980493.